Jessica Madow, APRN
Nurse Practitioner · Orlando, FLNPI 1992339626
Payments from drug & device makers
Across 644 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$3K
- AbbVie$2K
- SK Life Science, Inc.$1K
- Livanova USA, Inc.$901
- Pfizer$791
- Eisai Inc.$693
- plus $5K from 28 others
What the payments were for
- Travel & lodging$2602%
- Food & beverage$13,55998%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 108 | $3,071 |
| AbbVie(2 entities) | 102 | $1,857 |
| SK Life Science, Inc. | 40 | $1,153 |
| Livanova USA, Inc. | 31 | $901 |
| Pfizer | 49 | $791 |
| Eisai Inc. | 30 | $693 |
| Lilly USA, LLC | 42 | $622 |
| Jazz Pharmaceuticals Inc. | 25 | $599 |
| Teva Pharmaceuticals USA, Inc. | 30 | $554 |
| Neurelis, Inc. | 32 | $539 |
| Acadia Pharmaceuticals Inc | 20 | $350 |
| Catalyst Pharmaceuticals, Inc. | 14 | $333 |
| Sumitomo Pharma America, Inc. | 16 | $304 |
| Biohaven Pharmaceuticals, Inc. | 15 | $280 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $242 |
| Sunovion Pharmaceuticals Inc. | 11 | $203 |
| Amgen(2 entities) | 10 | $199 |
| GE HealthCare | 7 | $174 |
| Biogen | 9 | $161 |
| Otsuka America Pharmaceutical, Inc. | 7 | $147 |
| Novartis | 5 | $90 |
| Lundbeck LLC | 3 | $78 |
| Impel Pharmaceuticals Inc. | 3 | $63 |
| Aquestive Therapeutics, Inc. | 3 | $61 |
| Aucta Pharmaceuticals, Inc. | 5 | $56 |
| Supernus Pharmaceuticals, Inc. | 3 | $52 |
| Amneal Pharmaceuticals LLC | 3 | $52 |
| Upsher-smith Laboratories LLC | 2 | $51 |
| Neurocrine Biosciences, Inc. | 2 | $43 |
| Otter Pharmaceuticals, LLC | 1 | $29 |
| Immedica Pharma US, Inc. | 1 | $22 |
| AstraZeneca | 1 | $18 |
| Almatica Pharma LLC | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$260
- Fintepla$125
- EPKINLY$123
- Leqembi$118
How this compares
$13,819 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 29 | $163,614 |
| BriviactBrivaracetam | 96 | $157,006 |
| QuliptaAtogepant | 108 | $130,290 |
| Nurtec OdtRimegepant Sulfate | 72 | $104,352 |
| BanzelRufinamide | 11 | $79,402 |
| OnfiClobazam | 11 | $73,782 |
| UbrelvyUbrogepant | 42 | $71,304 |
| FycompaPerampanel | 42 | $63,243 |
| AptiomEslicarbazepine Acetate | 33 | $57,586 |
| XcopriCenobamate | 30 | $35,381 |
| VimpatLacosamide | 26 | $33,050 |
| Aimovig AutoinjectorErenumab-Aooe | 25 | $25,528 |
| Lamotrigine ErLamotrigine | 69 | $23,648 |
| Emgality PenGalcanezumab-Gnlm | 18 | $23,114 |
| Lacosamide | 115 | $19,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $1,857 | $201,594150 claims |
| UCB, Inc.Briviact, Vimpat | $3,071 | $190,057122 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $554 | $163,61429 claims |
| Eisai Inc.Banzel, Fycompa | $693 | $142,64553 claims |
| PfizerNurtec Odt, Zavzpret | $791 | $117,07784 claims |
| Lundbeck LLCOnfi | $78 | $73,78211 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $203 | $57,58633 claims |
| SK Life Science, Inc.Xcopri | $1,153 | $35,38130 claims |
| Upsher-smith Laboratories LLCTopiramate | $51 | $1,00652 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Orlando
- Jason RoyOrlando$95K
- Deborah ChandlerOrlando$60K
- Jennifer BlattnerOrlando$24K
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.